Skip to content
Subscriber Only

Lilly Tops Estimates as Cymbalta Sales Counter Zyprexa Drop

Eli Lilly & Co. reported fourth-quarter profit that beat analysts’ estimates as higher sales of its depression and diabetes medicines helped to counter a 44 percent plunge in revenue from the schizophrenia drug Zyprexa.

Net income fell 27 percent to $858.2 million, or 77 cents a share, the Indianapolis-based company said today in a statement. Profit excluding one-time items beat by 6 cents the average of 17 analyst estimates compiled by Bloomberg.